Amgen Stock Rises 0.34 Percent Amid Positive Clinical Development Updates

Amgen's stock began trading at EUR 374.43 pre-market on September 30, 2026, marking a slight increase of 0.34 percent compared to the previous closing price at Lang & Schwarz.

This development comes as Amgen reported positive Phase 3 results for dazodalibep in Sjögren's disease. The OASIZ 301 study met its primary endpoint through Week 48 in patients with moderate to severe disease, according to a report published by Yahoo Finance on September 22, 2026.

In another clinical development update, Amgen received an FDA label update for IMDELLTRA, which reduced the recommended monitoring times for the first two doses from 22 to 24 hours to 6 to 8 hours.